By John Schroyer
Overjoyed. Infuriated. Apathetic.
That’s the marijuana industry’s response to the U.S. Drug Enforcement Administration’s decision to say “no” to cannabis rescheduling and “yes” to medical cannabis research. Here’s a closer look at the business and political implications of this week’s DEA verdict.
1. New Industry Niche
That was at the top of an email from Dr. Sue Sisley, who’s been striving for years to put together a study on the medical efficacy of cannabis for patients with…